Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.

Ramos, Mafalda; Cummings, Michael H; Ustyugova, Anastasia; Raza, Syed I; de Silva, Shamika U; Lamotte, Mark

Ramos, Mafalda; Cummings, Michael H; Ustyugova, Anastasia; Raza, Syed I; de Silva, Shamika U; Lamotte, Mark.

Afiliación

Ramos M; Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal.
Cummings MH; Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK.
Ustyugova A; Boehringer Ingelheim International GmbH, 55216, Ingelheim Am Rhein, Germany.
Raza SI; Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK.
de Silva SU; Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK.
Lamotte M; Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium. Mark.lamotte@iqvia.com.

Diabetes Ther ; 11(9): 2041-2055, 2020 Sep.

Article en En | MEDLINE | ID: mdl-32700188

Palabras clave

Cost-effectiveness; Costs and cost analysis; Diabetes mellitus; Empagliflozin; GLP-1 receptor agonists; Oral semaglutide; SGLT-2 inhibitors; Treatment intensification; United Kingdom

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Diabetes Ther Año: 2020 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google